Praxis Precision Medicines shares are trading higher after the company announced it received Breakthrough Therapy Designation from the FDA for elsunersen.

Benzinga Newsdesk www.benzinga.com Positive 95.4%

Neg 0% Neu 0% Pos 95.4%

Comments

No comments yet. Be the first!